Description of the medicine: Mifepristone (Mifepristone)
11- [4- (Dimethylamino) phenyl] -17-hydroxy-17- (1-propynyl) extra-4,9-dien-3-one.
Synonyms: Mifegin, Pencrofton, Mifegyne, Pencrofton.
Prevents the binding of progesterone to the corresponding receptors.
Quickly absorbed in the digestive tract, T Ѕ is 1 hour.
Apply to terminate uterine pregnancy in the early stages (up to 42 days).
Assign inside 0.6 g once. If miscarriage does not occur after 2 weeks, vacuum aspiration is performed.
Possible side effects: uterine bleeding, discomfort and pain in the lower abdomen, weakness, headache, vomiting and nausea; contributes to the development of infectious diseases of the uterus and genitourinary system.
The drug is contraindicated in pregnancy exceeding 42 days, adrenal insufficiency, hemostatic disorders, anemia.
Apply only in a hospital setting.
Release form: tablets on 0,2 g (N. 3, 30).